Volume | 523,135 |
|
|||||
News | - | ||||||
Day High | 1.46 | Low High |
|||||
Day Low | 1.39 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Checkpoint Therapeutics Inc | CKPT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.42 | 1.39 | 1.46 | 1.44 | 1.42 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,351 | 523,135 | $ 1.41 | $ 737,249 | - | 1.30 - 3.62 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 990 | $ 1.43 | USD |
Checkpoint Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
33.41M | 23.53M | - | 103k | -51.85M | -2.20 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Checkpoint Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CKPT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.62 | 1.68 | 1.39 | 1.45 | 381,682 | -0.18 | -11.11% |
1 Month | 2.06 | 2.08 | 1.39 | 1.69 | 348,424 | -0.62 | -30.10% |
3 Months | 1.99 | 2.355 | 1.39 | 1.92 | 413,376 | -0.55 | -27.64% |
6 Months | 2.04 | 3.62 | 1.36 | 2.12 | 653,598 | -0.60 | -29.41% |
1 Year | 2.88 | 3.62 | 1.30 | 2.19 | 452,907 | -1.44 | -50.00% |
3 Years | 28.30 | 46.40 | 1.30 | 18.27 | 645,832 | -26.86 | -94.91% |
5 Years | 35.40 | 53.762 | 1.30 | 22.23 | 608,908 | -33.96 | -95.93% |
Checkpoint Therapeutics Description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). |